Skip to main content
. 2016 Feb 11;2016:1959270. doi: 10.1155/2016/1959270

Figure 3.

Figure 3

Effect of substance P receptor antagonist pretreatment on doxorubicin-induced, reactive oxygen species (ROS) production in cardiomyocytes and triple-negative breast cancer cells. Levels of ROS as determined by the DCFDA assay, in response to DOX in aprepitant pretreated versus untreated rat H9C2 cardiomyocytes (a) and MDA-MB 231 TNBC cells (b) ( p ≤ 0.05, ANOVA, n = 2, for both). Only statistical comparisons between DOX and DOX + AP are shown.